Cherie Stabler is internationally recognized for her research and her educational program is focused on the generation of translational biomaterial platforms for cellular implants, with a particular emphasis on cell-based therapies for Type 1 diabetes. Her novel bioactive materials aim to enhance graft survival and utilize local and translational approaches to dampen host immunological responses. Cherie's work spans from designing new biomaterials to seeking FDA clearance for combinatory products.
Areas of Expertise (5)
Media Appearances (1)
Faculty Insights Webinar featuring Cherie Stabler
UF Herbert Wertheim College of Engineering tv
Biomedical engineering advancements in the treatment of Type 1 diabetes.
The Foundation for Engineering a Pancreatic Islet NicheFrontiers in Endocrinology
Smit N. Patel, et. al
Progress in diabetes research is hindered, in part, by deficiencies in current experimental systems to accurately model human pathophysiology and/or predict clinical outcomes. Engineering human-centric platforms that more closely mimic in vivo physiology, however, requires thoughtful and informed design. Summarizing our contemporary understanding of the unique and critical features of the pancreatic islet can inform engineering design criteria.
Designing biomaterials for the modulation of allogeneic and autoimmune responses to cellular implants in Type 1 DiabetesActa Biomaterialia
Magdalena M. Samojlik, Cherie L. Stabler
The effective suppression of adaptive immune responses is essential for the success of allogeneic cell therapies. In islet transplantation for Type 1 Diabetes, pre-existing autoimmunity provides an additional hurdle, as memory autoimmune T cells mediate both an autoantigen-specific attack on the donor beta cells and an alloantigen-specific attack on the donor graft cells. Immunosuppressive agents used for islet transplantation are generally successful in suppressing alloimmune responses...
Strategies for durable β cell replacement in type 1 diabetesScience
Todd M. Brusko, et. al
Technological advancements in blood glucose monitoring and therapeutic insulin administration have improved the quality of life for people with type 1 diabetes. However, these efforts fall short of replicating the exquisite metabolic control provided by native islets. We examine the integrated advancements in islet cell replacement and immunomodulatory therapies that are coalescing to enable the restoration of endogenous glucose regulation.